Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Twist Bioscience (TWST) to $65 from $50 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where they raised 2026 revenue guidance on broad based momentum.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience upgraded to Outperform from Market Perform at Leerink
- Twist Bioscience Charts Profitable Path Amid Strong Growth
- Twist Bioscience price target raised to $65 from $55 at Barclays
- Midday Fly By: GameStop offers to buy eBay, Norwegian reports mixed Q1
- Twist Bioscience sees Q3 revenue $114M-$115M, consensus $111.27M